Stockscreener 앱 받기
8.52
2.41%
-0.21
전일 마감가:
$8.73
열려 있는:
$8.62
하루 거래량:
170.15K
Relative Volume:
0.83
시가총액:
$3.21B
수익:
$391.87M
순이익/손실:
$-441.45M
주가수익비율:
-4.6054
EPS:
-1.85
순현금흐름:
$-301.21M
1주 성능:
-7.29%
1개월 성능:
-15.73%
6개월 성능:
-36.98%
1년 성능:
-28.46%
1일 변동 폭
$8.50
$8.80
1주일 범위
$8.50
$9.26
52주 변동 폭
$7.35
$13.70
Alvotech Stock (ALVO) Company Profile
ALVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
8.52 | 3.21B | 391.87M | -441.45M | -301.21M | -1.85 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.75 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
154.96 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
9.96 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.68 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.40 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 개시 | UBS | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-09-21 | 개시 | Barclays | Equal Weight |
| 2022-09-07 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-06 | 다운그레이드 | Citigroup | Buy → Sell |
| 2022-07-26 | 개시 | Citigroup | Buy |
모두보기
Alvotech 주식(ALVO)의 최신 뉴스
Alvotech: A Fast Expanding Biosimilar Concern (NASDAQ:ALVO) - Seeking Alpha
Alvotech taps Linda Jónsdóttir as CFO - MSN
Alvotech Boosts Packaging Abilities With Ivers-Lee Acquisition - insights.citeline.com
Alvotech Names Chief Financial Officer - Contract Pharma
Alvotech acquires Ivers-Lee Group - MSN
Alvotech Appoints New CFO Amidst Continued Growth - TipRanks
Alvotech names veteran Linda Jónsdóttir finance chief - MSN
Iceland's Alvotech Names New CFO - MarketScreener
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer - MarketScreener
Alvotech expands biosimilars capabilities with Ivers-Lee acquisition - Yahoo Finance
Alvotech Acquires Ivers-Lee Group - Contract Pharma
Alvotech Acquires Ivers-Lee to Boost Biosimilar Packaging Capacity - TipRanks
Why Is Alvotech Stock Trading Higher On Wednesday? - Benzinga
Alvotech expands biosimilar production capabilities with acquisition of Swiss packaging specialist Ivers-Lee - grafa.com
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland - The Manila Times
Alvotech Expands Biosimilar Production Capacity with Acquisition of Ivers-Lee Group - Nasdaq
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland - MarketScreener
Alvotech Expands Global Manufacturing Network: Strategic Acquisition Powers Launch of 3 New Biosimilars - Stock Titan
Alvotech (ALVO) Stock Analysis: A Deep Dive Into Its 98% Upside Potential - DirectorsTalk Interviews
Alvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma - MSN
Alvotech and Advanz Pharma: A Bold Play for $13.8 Billion in European Biosimilars - AInvest
Alvotech S.A. Reports Increase in Own Shares to 6.73%, Exceeding 5% Voting Rights Threshold - Nasdaq
Alvotech Q1 Earnings Reveal Massive 786% Product Revenue Jump, Raises Full-Year Guidance to $700M - Stock Titan
Alvotech and Advanz Pharma Forge European Biosimilar Agreement - TipRanks
Alvotech Partners with Advanz for Cimzia® biosimilar in Europe - grafa.com
Alvotech and Advanz Pharma Enter into European Supply and - GlobeNewswire
Alvotech Grants 99,136 Stock Options to Board Directors, RSUs Vest for Insiders - Stock Titan
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility - Yahoo Finance
Alvotech, Kashiv, Advanz announce study of AVT23 met primary endpoint - TipRanks
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewswire
European Regulator Backs New Eylea Biosimilar: Alvotech Eyes $3B European Market Opportunity - Stock Titan
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Cancer Drug Pembrolizumab - geneonline.com
Day 8 of Loss Streak for Alvotech Stock with -15% Return (vs. -32% YTD) [6/18/2025] - Trefis
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar of Merck’s Keytruda for Global Cancer Treatment - geneonline.com
Alvotech (NASDAQ:ALVO) Short Interest Up 75.2% in May - MarketBeat
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan - Center for Biosimilars
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Keytruda Cancer Drug - geneonline.com
Alvotech, Dr. Reddy’s to co-develop Keytruda biosimilar - Drug Store News
Alvotech (NASDAQ:ALVO) Trading Down 3.3%Should You Sell? - MarketBeat
Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar - MSN
Millennium Management LLC Trims Position in Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Merck's Keytruda - MSN
Linklaters Advises Syndicate on Alvotech’s SEK 750 Million Private Placement - Global Legal Chronicle
Alvotech Completes Private Placement to Boost Shareholder Base - TipRanks
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Pembrolizumab Used in Cancer Treatment - geneonline.com
Alvotech completes private placement with 40 institutional investors By Investing.com - Investing.com Australia
Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors - The Manila Times
Alvotech Completes Successful Private Placement with Global Institutional Investors - Nasdaq
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors - Yahoo Finance
REG-Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors - TradingView
Alvotech Attracts 40 New Global Investors in Strategic Private Placement, 80% First-Time Buyers - Stock Titan
Alvotech (ALVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
자본화:
|
볼륨(24시간):